Judy it's a clinical trial of an anti-Her2 vaccine being conducted at University of Washington in Seattle. They've had a trial of women not on Herceptin and now they're running a trial of women on Herceptin and either NED/in remission or with stable disease. The first criteria is a volunteer's blood has to be positive for HLA A2 which is an antibody present in only 40-50% of people. This antibody is easily measurable and so they will use it as a marker to determine if study participants are developing an immune response against Her2neu!

Lolly what would the advantage of the trial be? Are the effects of the vaccine similar to the Herceptin most Her2 patients are getting?